During the past decade, several outbreaks of severe systemic disease associated with Feline calicivirus (FCV) have occurred in the USA and the UK. This new disease has caused high mortality in the affected animals and has been termed virulent systemic (VS)-FCV disease. Currently, there are no genetic or in vitro diagnostic methods to distinguish viruses isolated from cases of VS-FCV disease from other isolates. Here, five in vitro properties, as well as the capsid and proteinase-polymerase (pro-pol) sequences, of a set of FCV isolates that included seven isolates from five distinct VS-FCV outbreaks ('VS isolates') were investigated. Although all of the FCV isolates investigated had similar kinetics of growth under single-cycle conditions, VS isolates infected tissue-culture cells more efficiently under multiple-cycle growth conditions. Moreover, it was found that cells infected with VS isolates showed cytopathic effects earlier than cells infected with non-VS isolates, although no difference in relative ATP levels were noted at times when morphological changes were first seen. Both VS-and other (non-VS) isolates of FCV demonstrated similar temperature stabilities. Phylogenetic analyses and alignments of the capsid and pro-pol regions of the genome did not reveal any conserved changes that correlated with virulence, and the VS isolates did not segregate into a unique clade. These results suggest that VS isolates have arisen independently several times since first being described and can spread more efficiently in tissue culture than other isolates when infected at low multiplicity.
INTRODUCTION
Feline calicivirus (FCV) is a common pathogen of cats. Infected cats can be clinically normal or show signs of oral ulceration and/or mild upper respiratory disease. Less commonly, limping, abortion and severe pneumonia can occur; however, fatal disease is unusual Pesavento et al., 2004; Coyne et al., 2006) . The prevalence of avirulent or mildly virulent FCV in multiple-cat environments is as high as 36 % (Binns et al., 2000; Bannasch & Foley, 2005) . During the last decade, however, epizootics of a severe form of FCV disease with mortality rates as high as 50 % have occurred Coyne et al., 2006) . These epizootics, designated virulent systemic (VS-) FCV, have been reported in the USA and recently in the UK (Pedersen et al., 2000; Schorr-Evans et al., 2003; Hurley et al., 2004; Coyne et al., 2006) . The clinicopathological features of VS-FCV disease differ substantially from those of 'classical' FCV disease; reported signs of VS-FCV disease include high persistent fever, anorexia, depression, facial and limb oedema, sores or alopecia on the face, pinnae and feet, pulmonary oedema, coagulation abnormalities, pancreatitis and hepatic necrosis (Pedersen et al., 2000; Hurley et al., 2004; Pesavento et al., 2004) . In all of the reported outbreaks, vaccinated cats have been affected, suggesting that current vaccines may not protect against VS disease (Coyne et al., 2006) .
FCV belongs to the genus Vesivirus of the family
Caliciviridae and contains a positive-sense RNA genome (approx. 7.6 kb) packaged within a non-enveloped capsid. The icosahedral capsid is assembled from 90 homodimers of the major capsid protein VP1. Two genogroups of FCV have been defined by phylogenetic analysis. Of the isolates characterized, only isolates from Japan are members of genogroup II (Sato et al., 2002) , whilst all other VS-FCV isolates studied to date appear to be members of genogroup I (Geissler et al., 1997; Glenn et al., 1999) . All FCVs are considered to belong to a single, antigenically diverse serotype, but individual isolates vary in their levels of crossneutralization (Kalunda et al., 1975) . Initial reports indicate that VS-FCV isolates cannot be distinguished genetically from non-VS-FCV isolates Abd-Eldaim et al., 2005; Foley et al., 2006) .
Here, we characterized the in vitro growth properties, stabilities, cytopathic effects and sequences of seven VS-FCV isolates from five distinct VS-FCV outbreaks and compared them with those of the F9 vaccine strain and three non-VS-FCV clinical isolates. Based on the results herein, we conclude that the VS-FCV isolates that we analysed share the common properties of rapid growth kinetics and an increased propensity to spread in tissue culture in vitro. These properties appear to differ from those of both the F9 vaccine strain and the three non VS-FCV isolates and may in part explain the increased virulence of these viruses in vivo.
METHODS
Cells and viruses. Crandell feline kidney (CRFK) cells were grown in Eagle's minimal essential medium (EMEM) (CellGro) supplemented with 5 % fetal bovine serum (FBS; HyClone), 100 U penicillin ml
21
, 100 mg streptomycin ml 21 , 0.25 mg amphotericin B ml 21 , 1 mM sodium pyruvate and non-essential amino acids (CellGro). The clinical FCV isolates investigated in this study and the analyses performed are listed in Table 1 and -796 will be referred to as 'non-VS'. This designation is made based on the clinical history that accompanied the isolates. The F9 vaccine strain (VR-782) of FCV was obtained from the ATCC. Third-passage virus stocks were prepared from twice-plaque-purified viruses amplified in CRFK cells.
Plaque assay. Viruses were titrated on CRFK cells. In brief, confluent CRFK monolayers were inoculated with serial virus dilutions in Dulbecco's modified Eagles's medium (DMEM) (CellGro) with 0.1 % BSA (Calbiochem). Virus adsorption was carried out at room temperature for 60 min with gentle agitation every 10 min. Monolayers were then overlaid with 3 ml EMEM containing 5 % FBS, 100 U penicillin ml
, 100 mg streptomycin ml
, 0.25 mg amphotericin B ml 21 , 1 mM sodium pyruvate, non-essential amino acids and 1 % Bacto-agar (Difco Laboratories). After incubation at 37 uC for 48 h in humidified 5 % CO 2 , the overlay was removed, the cells were fixed with 10 % buffered formalin (Fisher) and stained with 1 % (w/v) crystal violet solution. After washing, the plaques were counted and titre was expressed as p.f.u. ml 21 . Table 2 ). Determination of ORFs and amino acid sequence was performed by using Vector NTI Advance (Invitrogen Life Technologies). Sequence alignments were carried out by using CLUSTAL_X (Thompson et al., 1997) . Similarity tables were constructed by using Vector NTI Advance. Construction of phylogenetic trees inferred from nucleotide sequence was performed by using three methods: the distance (neighbour-joining) method using the CLUSTAL_X software, the Bayesian method with the software MRBAYES (Huelsenbeck & Ronquist, 2001; Ronquist & Huelsenbeck, 2003) and the maximum-likelihood method using the software PAUP* version 4.0 beta (Sinauer Associates). Neighbour joining-and maximum likelihood-generated trees were bootstrapped with the corresponding, aforementioned software. Construction and bootstrapping of phylogenetic trees inferred from amino acid sequence were performed by using CLUSTAL_W, utilizing the BLOSUM series (80, 62, 40 and 30) weight matrices for proteins. Constructed trees were visualized by using NJPLOT (Perriere & Gouy, 1996) .
Temperature-inactivation and -stability experiments. Thermal inactivation of virus isolates was performed by using a thermal cycler (MyCycler; Bio-Rad). Virus samples were incubated at 37.0, 41.8, 46.2, 52.2, 56.9 and 62.0 uC in thin-wall PCR tubes (Fisher) for 30 min, then plaque-titrated. Virus stability was investigated by maintaining virus in aliquots at room temperature and at 4 and 280 uC for up to 10 weeks. Aliquots in triplicate were plaquetitrated at regular intervals.
Generation of single-and multiple-cycle growth curves.
CRFK cell monolayers were infected with different FCV isolates at multiplicities of 5 and 0.01 for single-and multiple-cycle growth curves, respectively. Virus was adsorbed to cells for 1 h at room temperature in DMEM plus 0.1 % BSA; EMEM plus 5 % FBS supplemented as above was then added and the cells were incubated for various times at 37 uC in 5 % CO 2 . At various times post-infection (p.i.), samples were frozen and stored at 280 uC for later titration. Prior to plaque assay, all samples were frozen and thawed three times. Virus growth at each time point was calculated by subtracting the log 10 (p.f.u. ml 21 ) at T=0 from the log 10 (p.f.u. ml 21 ) measured at the time point. Results are expressed as the change in plaque titre over time, with the mean and SD of three replicates shown.
Cell-viability assay. The viability of infected CRFK cells was evaluated by using a commercial assay of ATP levels (CellTitre-Glo reagent; Promega) according to the manufacturer's recommendations. Ninety-six-well plates were read by using a Veritas microplate luminometer (Turner Biosystems). Relative luminescence units of experimental wells were compared with those of control wells to determine percentage change in ATP levels.
Statistical analyses. Comparisons of titres between sets of three replicates were analysed by ANOVA using the Analyse-it (Analyse-it Software) statistical analysis add-in for Microsoft Excel. Graphs were prepared by using KaleidaGraph (Synergy Software).
RESULTS

Single-cycle kinetics of growth of different FCV isolates in CRFK cells
We compared the growth kinetics of nine FCV isolates that differed in virulence (Table 1) . We found that all of the FCV isolates tested grew rapidly during a single round of virus replication that was characterized by a lag phase of about 3.5 h, followed by exponential growth that lasted 3-4.5 h (Fig. 1a) . Peak yields of virus were produced for all except the F9 vaccine strain at 8-12 h p.i. We noted that virus yield of all the isolates except for F9 had decreased by 0.5-1 log 10 from peak titre (at 8-12 h p.i.) by 24 h p.i. The single-cycle growth kinetics of VS-FCV isolates were not statistically significantly different from those of non-VS isolates; however, cells infected with the VS-FCV isolates Ari and Deuce yielded the most virus (2.5 log 10 ). We conclude that FCV isolates have a short replicative cycle in CRFK cells (10-12 h) and that FCV isolates of differing virulence have similar single-cycle growth kinetics, but may differ in the final yield of virus produced.
Multiple-cycle kinetics of growth of FCV in CRFK cells
We noted that virulent FCV isolates tended to produce larger plaques (data not shown) and hypothesized that these isolates would spread faster than less virulent isolates in tissue culture. We therefore examined the growth kinetics of three VS-FCV isolates, two non-VS isolates and the F9 vaccine strain during multiple replicative cycles to evaluate their ability to spread in tissue culture. Consistent with their larger plaque size, we found that the growth kinetics of VS-FCV isolates were faster than those of non-VS isolates (Fig. 1b) . By 4 h p.i., the titres of VS-FCV isolates were increasing exponentially and had yielded 2 log 10 infectious virus. In contrast, the F9 vaccine strain and isolate had not yet entered exponential growth. FCV-127, a non-VS isolate that produced large plaques, was growing exponentially at 4 h p.i., but had produced 10-fold less infectious virus than the three VS-FCV isolates. The differences in log titres at 4 and 8 h p.i. between the VS-FCV and non-VS isolates were statistically significant, as determined by ANOVA (P<0.0001). The final yields of virus varied; however, the two highest yields (approx. 5.5 and 4.8 log 10 ) were attained by VS-FCV isolates Deuce and Kaos, respectively. From these results, we conclude that VS-FCV isolates appear to produce infectious virions earlier when cells are infected at low multiplicity and may attain higher yields than less virulent isolates in CRFK cells.
Cytopathic effect of different FCV isolates
During the multiple-cycle growth-kinetics experiments, we noted that cells infected with VS-FCV isolates displayed morphological changes of rounding and detachment from the vessel surface earlier than other FCV isolates (Fig. 2a) . From 14 h p.i. onwards, we frequently observed clusters of VS-FCV-infected cells that were rounded up and detached partially or fully from the plate surface. In contrast, few non-VS isolate-infected cells displayed such morphological changes at 14 h p.i., and larger clusters of cells with such morphological alterations were absent. Non-VS isolate FCV-127, which was isolated from a kitten with severe pneumonia, caused more severe morphological changes than isolate FCV-796, suggesting that the severity of the cytopathic effects observed correlated in part with virulence. These observations suggested that VS-FCV isolates caused increased cytopathogenicity. The mechanisms that underlie FCV cytopathogenicity are not fully understood, although FCV infection is known to induce apoptosis (Roberts et al., 2003; Sosnovtsev et al., 2003; Natoni et al., 2006) . To test the possibility that VS-FCV isolates caused increased cytopathic effect in infected cells, we measured the intracellular ATP levels of cells infected with VS-FCV, non-VS isolates and the F9 vaccine strain at different times after infection in cells infected at multiplicities of 0.01 and 5 (Fig. 2b, c) . Intracellular ATP levels have been used to quantify the cytotoxic effect of the cytokine tumour necrosis factor alpha (Crouch et al., 1993) and as an indicator of the cytopathic effect of murine leukemia virus on CHO-K1 cells (Bruce et al., 2005) . Under multiple-cycle growth conditions (m.o.i.=0.01), at 14 h p.i., cells infected with VS-FCV isolates had ATP levels that were equal to or higher than control levels, despite obvious changes in cell morphology (Fig. 2a) . ATP levels in cells infected with all FCV isolates diverged from control levels by 16-20 h p.i. (Fig. 2b) . Non-VS isolates FCV-796 and -131 demonstrated the most rapid decrease in ATP, with levels at 50 % of control levels at 20 h p.i. For all of the isolates that we investigated, the cellular ATP levels dropped to 25-50 % of control levels by 24 h p.i. Under single-cycle growth conditions (m.o.i.=5), ATP levels in infected cells fell below control levels at 10-14 h p.i. (Fig. 2c ). Cells infected with the F9 vaccine strain displayed the earliest divergence from uninfected-control ATP levels at 10 h p. (Fig. 3) . The F9 vaccine strain was most sensitive to thermal inactivation, losing all infectivity following 30 min incubation at 52.2 uC. The other isolates were inactivated fully at 56.9 u C, except for isolate FCV-5 (inactivated fully at 62 u C). We conclude that all of the isolates that we examined were more resistant to thermal inactivation than F9, but exhibited differing temperature stabilities with respect to each other.
Stability of different FCV isolates at room temperature and at 4 and "80 ‡ C
We further evaluated the stabilities of different FCV isolates by assaying their infectivity following extended incubations at room temperature and at 4 and 280 u C (Fig. 4) . Isolates stored at room temperature lost 2-5 log 10 infectivity after 3 days, with the two VS-FCV isolates Deuce and FCV-5 and the non-VS isolate FCV-127 decreasing in infectivity by 2-3 log 10 and the F9 vaccine strain and non-VS isolate FCV-796 decreasing by 4-5 log 10 . By day 6, isolates FCV-5, -796 and F9 had lost infectivity completely. FCV-Deuce lost infectivity completely by day 10, whilst isolate FCV-127 retained a low level of infectivity at the conclusion of the 12 day experiment (Fig. 4) . We noted that, as virus titres dropped, the variability of the plaque assays increased, with SD values ranging from 0.75 log 10 to 2 log 10 . We found no obvious correlation between the temperature stability of different FCV isolates and their virulence.
When a limited set of isolates, the F9 vaccine strain and two VS-FCV isolates (FCV-5 and Deuce), were maintained at 4 uC, we observed that the F9 vaccine strain began to drop in titre by the tenth day of the experiment (Fig. 4) . The VS-FCV isolates maintained full infectivity until day 21. By the third week, all isolates exhibited similar rates of infectivity loss and, by 6-10 weeks, had lost infectivity completely. Although the two VS-FCV strains demonstrated enhanced stability over the vaccine strain at 4 u C during the first 2 weeks of storage, further testing will be necessary to confirm that VS-FCV isolates are more stable at 4 uC than other FCV isolates. Similar to our findings above, as virus titres dropped, the variability of the plaque assays increased. None of the isolates tested lost infectivity when stored at 280 u C for 8 weeks (Fig. 4) .
Sequence comparison of VS-FCV isolates and other FCV isolates
Abd-Eldaim et al. (2005) and Foley et al. (2006) have suggested that certain residues within the hypervariable region of the capsid protein sequence are unique to VS-FCV isolates. We therefore sequenced the capsid VP1-encoding second ORF of the FCV genome for all of the isolates and performed nucleotide and primary amino acid sequence alignments and phylogenetic analyses to investigate the relatedness of these sequences and 37 other FCV complete capsid sequences (Table 2 ). Capsid amino acid sequence alignments (CLUSTAL_W) revealed that no residues were unique to the VS-FCV isolates that we investigated (data not shown). We used Rabbit hemorrhagic disease virus (RHDV), a calicivirus in the genus Lagovirus, as an outgroup to root the phylogenies. By using nucleotide (neighbour-joining method)-and amino acid (BLOSUM)-based phylogenies, we found that the VS-FCV isolates did not form a unique clade (Fig. 5a, b) . As expected, isolates collected from the same outbreak of VS-FCV in Los Angeles, CA, USA, in 2002 (George Walder, Jengo and Kaos) clustered together in nucleotide and amino acid analyses, with determined bootstrap values of 100 %. The VS-FCV isolates Ari, Georgie, Deuce and FCV-5, as well as two other previously described VS-FCV isolates (Abd-Eldaim et al., 2005), were not related closely. Trees generated by utilizing the Bayesian method and maximum-likelihood method of phylogenetic inference also showed a clustering of the three VS-FCV isolates from the Los Angeles outbreak, whilst the remainder of the VS-FCV isolates were scattered throughout the tree (data not shown).
We also sequenced the portion of the first ORF that encodes pro-pol. Sequences from isolates investigated in this paper were compared with 14 previously published pro-pol sequences (Table 2 ). Similar to results from the capsid region, pro-pol sequence alignments (CLUSTAL_W) revealed no residues unique to the VS-FCV isolates investigated. The overall nucleotide identity was 80.6±3.1 % and the amino acid identity was 92.9±2.1 %. This was not significantly different from the nucleotide (82.6±5.4 %) or primary amino acid (94.4±2.2 %) sequence similarity between the VS-FCV isolates investigated. Phylogenetic trees were rooted as described above, using the sequence of the RHDV pro-pol. Both nucleotide (neighbour-joining method)-and amino acid (BLOSUM)-based phylogenies were similar to those of the capsid sequences, and VS-FCV isolates did not segregate from other FCV isolates (Fig. 6a,  b) . The three isolates from the 2002 Los Angeles outbreak grouped together (bootstrap values of 100 %). The sequences of the other VS-FCV isolates Deuce, Georgie, FCV-5, Ari and the two Tennessee isolates were not related closely. Similar results were obtained when phylogenies were inferred by using Bayesian and maximum-likelihood methods (data not shown). We conclude that VS-FCV isolates do not represent a unique clade of FCV, but instead appear to have arisen independently multiple times in different geographical locations.
DISCUSSION
The reported outbreaks of VS-FCV have been characterized by severe clinical disease, rapid spread and high mortality rates (Pedersen et al., 2000; Schorr-Evans et al., 2003; Hurley et al., 2004; Pesavento et al., 2004; Coyne et al., 2006) . As vaccinated cats appear to be as susceptible to this form of FCV as unvaccinated cats, disease control is currently problematic. A major difficulty is that viruses associated with VS disease cannot be distinguished from other FCV isolates in vitro. One study reported that sequences from a small set of VS-FCV isolates were no more similar to each other than to other non-VS field isolates of FCV (AbdEldaim et al., 2005) . Despite this, the disease has been reproduced in experimental animals, indicating that the genetic differences are probably hidden by the high variability of the FCV genome (Pedersen et al., 2000) . The initial goal of our study was to identify in vitro phenotypes of VS-FCV isolates that would distinguish them from other, less virulent FCV isolates and that could be used as a correlate to identify the underlying genotype(s) associated with FCV virulence.
Previous reports have described the single-cycle growth kinetics of 'classical' isolates of FCV (Studdert et al., 1970; Kreutz & Seal, 1995) . This is the first report of single-cycle growth kinetics of VS-FCV isolates, as well the first report of multiple-cycle growth kinetics for any FCV isolate. All of the FCV isolates that we investigated displayed similar singlecycle growth kinetics, and our findings are generally similar to those published previously (Studdert et al., 1970; Kreutz & Seal, 1995) . Although VS-and non-VS-FCV isolates displayed similar kinetics, the VS-FCV isolates tended to replicate to higher titres, suggesting higher yields per cell. In contrast, during multiple-cycle growth, we observed that the three VS-FCV isolates produced infectious virions earlier and/or to substantially higher titres than the vaccine/non-VS isolate group. Given that the VS-and non-VS isolates had similar kinetics of growth during a single cycle of replication, these findings indicate that VS-FCV isolates infect CRFK cells more efficiently than do non-VS strains. Such efficiency suggests that differences in virus attachment, entry, establishment of replication sites or release from cells may determine the increased growth of VS-FCV isolates and perhaps play a role in the increased pathogenicity of VS-FCV isolates.
In addition to more efficient infection, we also observed that cells infected with VS-FCV isolates at low multiplicities displayed cytopathic effects earlier than those infected with non-VS field isolates or the vaccine strain. Surprisingly, VS-FCV-infected cells had similar or higher ATP levels than did the uninfected controls at time points when cytopathic effects were first readily seen. Under single-cycle conditions, VS-FCV-infected cells maintained ATP levels for longer than the non-VS isolates. By maintaining cellular ATP levels, VS-FCV isolates may delay the onset of the final stages of apoptosis, thus allowing the production and/or release of more virus particles. It was reported recently that intracellular pools of ATP and other nucleotides are able to block cytochrome c-initiated apoptosome formation and caspase activation directly (Chandra et al., 2006) . Alternatively, maintaining intracellular ATP levels may serve to promote energy-dependent apoptotic cell death and prevent cellular necrosis (Chiarugi, 2005) . This may prove advantageous to virus replication in vivo by limiting the inflammatory reaction initiated by necrotic cells.
Fomite transmission has been implicated as an important factor in the rapid spread observed during the documented Fig. 4 . Stability of FCV over time when maintained at room temperature (RT) and at 4 and "80 6C. Aliquots of virus were maintained at room temperature or at 4 or "80 6C for the indicated number of days, then the remaining infectivity was determined by plaque assay. Each data point represents the mean log 10 (p.f.u ml "1 ) of three replicates. As virus titres dropped, the variability of the plaque assays increased. Standard deviations ranged from 0.75 log 10 to 2 log 10 beginning on the fourth day of the RT experiment, and from 1.5 log 10 to 3 log 10 beginning on day 35 of the 4 6C experiment. Therefore, the SD bars have been omitted for clarity. Titres were also observed to oscillate around the zero titre mark for isolates FCV-5, Deuce, F9 and FCV-96 by values up to 1.5 log 10 (RT assay) and 3 log 10 (4 6C assay). These data points have also been omitted for clarity. The first data point indicating loss of infectivity is indicated by an asterisk. Isolates from cats diagnosed with VS disease are shown with solid lines and hollow markers. The vaccine strain and non-VS isolates are displayed with dashed lines and solid markers. . Phylogenetic analysis of FCV capsid nucleotide and protein sequences. Phylogenetic analysis was performed on the (a) nucleotide sequences and (b) protein sequences of ORF2 for all of the FCV isolates used in this study and 37 other FCV sequences obtained from GenBank. Trees were generated by using the nearest-neighbour distance method. Rabbit hemorrhagic disease virus (RHDV) was used as an outgroup for each analysis; outgroup branch lengths have been shortened for simplicity. *VS-FCV isolates sequenced in this paper; DVS-FCV isolates sequenced previously; dFCV field isolates sequenced in this paper. Vaccine strains are underlined and the strain name is provided in parentheses. Bootstrap values >90 % are indicated. (Pedersen et al., 2000; Hurley et al., 2004) . We therefore hypothesized that VS-FCV isolates might possess increased environmental stability over non-VS isolates. However, whilst individual isolates displayed minor differences in their sensitivity to temperature inactivation, there was no correlation with virulence. We noted, however, that the F9 vaccine strain was inactivated completely at a lower temperature than the other isolates that we tested, suggesting that some capsid stability was lost during the selection for attenuation of the F9 strain. The F9 strain has been used extensively to evaluate the sensitivity of caliciviruses to environmental inactivation by various methods (Duizer et al., 2004; Tree et al., 2005; Malik et al., 2006) . Our results suggest that these findings should be tempered by the knowledge that field strains may be more resistant to inactivation than vaccine strains.
VS-FCV outbreaks
Minor differences in stability between isolates after extended incubation at room temperature or 4 uC did not correlate with virulence. In contrast to a previous report that indicated that virions were more stable when maintained at 4 uC (Komolafe, 1979) , we found that all of the isolates that we tested lost infectivity when stored for longer than 2-3 weeks at 4 u C, but retained full infectivity when stored at 280 uC. The reasons for these differences are unclear, but may be due to stabilizing effects of serum proteins within the lysate (Komolafe, 1979) . Additionally, we also found that infectivity was maintained after as many as 56 freeze-thaw cycles (data not shown). Therefore, FCV appears to tolerate multiple freeze-thaw cycles without loss of infectivity, indicating that storage of viral lysates at 280 u C is optimal.
Previous analyses of the capsid and pro-pol sequences of VS-FCV isolates found them to be no more similar to each other than to other non-VS isolates Abd-Eldaim et al., 2005; Foley et al., 2006) . Our sequence analyses support these conclusions and suggest that the . Phylogenetic analysis of FCV proteinase-polymerase (pro-pol) nucleotide and protein sequences. Phylogenetic analysis was performed on the (a) nucleotide sequence and (b) protein sequence of pro-pol for all FCV isolates used in this study and 14 other FCV sequences obtained from GenBank. Trees were generated by using the nearest-neighbour distance method. Rabbit hemorrhagic disease virus (RHDV) was used as an outgroup for each analysis; outgroup branch lengths have been shortened for simplicity. *VS-FCV isolates sequenced in this paper; DVS-FCV isolates sequenced previously; dFCV field isolates sequenced in this paper. Vaccine strains are underlined and the strain name is provided in parentheses. Bootstrap values >90 % are indicated. different VS-FCV isolates have arisen independently in distinct geographical locations. These studies also suggested that there were amino acid sequences within the hypervariable region (residues 426-452) of the capsid that were unique to VS-FCV isolates. However, when we analysed all of the available VS-FCV sequences together, we found that there were no sequences or amino acid changes unique to all VS isolates in the capsid or pro-pol regions.
We recognize that many of our conclusions are based on two assumptions. The first is that the VS-FCV samples that we are characterizing still possess the virulent nature of the original isolate. Passage in tissue culture has been limited to prevent selection of variants. Furthermore, three of the isolates that we characterized have been used to reproduce VS-FCV disease in cats [Ari (Pedersen et al., 2000) ; FCV-5 (Rong et al., 2006) ; Kaos (P. A. Pesavento, unpublished data)]. Whilst the other isolates have not been tested in vivo, the experience thus far is that VS-FCV isolates can be passaged at least three times in tissue culture without loss of virulence, and perhaps up to 20 times (Rong et al., 2006) . The second is that all strains considered non-VS isolates do not cause VS disease. However, it is possible that many cases of VS-FCV go undetected. The investigated isolate FCV-127 originated from a shelter where numerous cats died due to pneumonia. In all experiments, isolate FCV-127 behaved more like a VS-FCV isolate than the other non-VS field isolates. Thus, we speculate that the differences in virus growth patterns that we noted between VS and non-VS viruses may in fact be shared by other 'virulent' FCV isolates. Currently, the only means to verify that a particular isolate causes VS disease is by reproducing the disease syndrome in an experimentally infected cat.
In summary, we have investigated several viral characteristics in an attempt to define an in vitro phenotype unique to VS strains. Our findings indicate that there are differences between VS and non-VS isolates that may serve as markers for virulence. We are currently evaluating further the genetic bases of these differences.
